Oramed Pharmaceuticals Inc. — Major Shareholding Notification 2012

Feb 14, 2012

SC 13G/A 1 jb13ga1-oramed_attara.htm jb13ga1-oramed_attara.htm Licensed to: Fried Frank Document Created using EDGARizer 2020 5.4.1.0 Copyright 1995 - 2009 Thomson Reuters. All rights reserved.

UNITED STATES

SECURITIES EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Amendment No. 1)

Under the Securities Exchange Act of 1934

Oramed Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

68403P104

(CUSIP Number)

December 31, 2011

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[ ] Rule 13d-1(b)

[X ] Rule 13d-1(c)

[ ] Rule 13d-1(d)

• The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Continued on following pages

Page 1 of 10 Pages

Exhibit Index: Page 9

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Attara Capital LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	(a) o (b) o
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES	5	SOLE VOTING POWER 6,948,570
BENEFICIALLY OWNED BY	6	SHARED VOTING POWER None
EACH REPORTING	7	SOLE DISPOSITIVE POWER 6,948,570
PERSON WITH	8	SHARED DISPOSITIVE POWER None

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,948,570
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.9%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Attara Fund, Ltd.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	(a) o (b) o
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands

NUMBER OF SHARES	5	SOLE VOTING POWER 6,948,570
BENEFICIALLY OWNED BY	6	SHARED VOTING POWER None
EACH REPORTING	7	SOLE DISPOSITIVE POWER 6,948,570
PERSON WITH	8	SHARED DISPOSITIVE POWER None

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,948,570
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.9%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) David M. Slager
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	(a) o (b) o
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Dutch

NUMBER OF SHARES	5	SOLE VOTING POWER 6,948,570
BENEFICIALLY OWNED BY	6	SHARED VOTING POWER None
EACH REPORTING	7	SOLE DISPOSITIVE POWER 6,948,570
PERSON WITH	8	SHARED DISPOSITIVE POWER None

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,948,570
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.9%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

Item 1(a). Name of Issuer:

Oramed Pharmaceuticals, Inc. (the “Issuer”).

Item 1(b). Address of Issuer’s Principal Executive Offices:

Hi-Tech Park 2/5 Givat-Ram PO Box 39098 Jerusalem 91390 Israel

Item 2(a). Name of Person Filing

This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

i)	Attara Capital LP (“Attara Capital”);
ii)	Attara Fund, Ltd. (“Attara Fund”); and
iii)	David Slager (“Mr. Slager”)

Item 2(b). Address of Principal Business Office or, if None, Residence

The address of the principal business office of each of Attara Capital and Mr. Slager is 767 Fifth Avenue, 12 th Floor, New York, New York 10153. The address of the Attara Fund is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands.

Item 2(c). Citizenship

i)	Attara Capital is a Delaware limited partnership;
ii)	Attara Fund is a Cayman Islands exempted company; and
iii)	Mr. Slager is a citizen of the Netherlands.

Item 2(d). Title of Class of Securities:

Common Stock, par value $0.001 per share (the “Common Stock”)

Item 2(e). CUSIP Number:

68403P104

ITEM 3. If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:

This Item 3 is not applicable.

Item 4. Ownership:

Item 4(a) Amount Beneficially Owned:

See Item 9 of the attached cover page.

Item 4(b) Percent of Class:

See Item 11 of the attached cover page.

Item 4(c) Number of Shares of which such person has:

(i)	Sole power to vote or direct the vote:
	See Item 5 of the attached cover page.
(ii)	Shared power to vote or direct the vote:
	See Item 6 of the attached cover page.
(iii)	Sole power to dispose or direct the disposition of:
	See Item 7 of the attached cover page.
(iv)	Shared power to dispose or direct the disposition of:
	See Item 8 of the attached cover page.

Attara Capital is the investment manager of the Attara Fund, the owner of record of the Common Stock reported herein. Mr. Slager is the managing member of the general partner of Attara Capital. All investment decisions are made by Mr. Slager, and thus the power to vote or direct the votes of the Common Stock reported herein, as well as the power to dispose or direct the disposition of the Common Stock reported herein is held by Mr. Slager through Attara Capital.

Item 5.	Ownership of Five Percent or Less of a Class:
	This Item 5 is not applicable.
Item 6.	Ownership of More than Five Percent on Behalf of Another Person:
	This Item 6 is not applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
	This Item 7 is not applicable.
Item 8.	Identification and Classification of Members of the Group:
	This Item 8 is not applicable.
Item 9.	Notice of Dissolution of Group:
	This Item 9 is not applicable.
Item 10.	Certification:

By signing below each of the Reporting Persons certifies that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, each of the Reporting Persons certifies that the information set forth in this statement is true, complete and correct.

Date: February 14, 2012
By:	/s/ David M. Slager
Name: David M. Slager
Title: Chairman

Date: February 14, 2012
By:	/s/ Alexandra Toohey
Name: Alexandra Toohey
Title: Director

Date: February 14, 2012
By:	/s/ David M. Slager
Name: David M. Slager

EXHIBIT INDEX

Ex.		Page No.
A.	Joint Filing Agreement, dated as of February 14, 2012 by and among Attara Capital LP, Attara Fund, Ltd. and David Slager	10

EXHIBIT A

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock, par value $0.001 per share, of Oramed Pharmaceuticals, Inc., dated as of February 14, 2012 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Date: February 14, 2012
By:	/s/ David M. Slager
Name: David M. Slager
Title: Chairman

Date: February 14, 2012
By:	/s/ Alexandra Toohey
Name: Alexandra Toohey
Title: Director

Date: February 14, 2012
By:	/s/ David M. Slager
Name: David M. Slager